Bolt Biotherapeutics Inc

NASDAQ:BOLTUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Contact Information

Headquarters

900 Chesapeake DriveREDWOOD CITY, CA, United States 94063

Phone

650-665-9295

Fax

302-531-3150

Executives

President, Chief Executive Officer, Chief Financial Officer, Director

William Quinn

Chief Operating Officer

Grant Yonehiro

Director

Jakob Dupont

Independent Director

Laura Berner

Independent Director

Kathleen Laporte